Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Bio-Rad gets EU QMS certificate for 40 QC products

May 2025—Bio-Rad Laboratories has received the EU quality management systems certificate under IVDR regulation (EU) 2017/746, enabling the CE-IVDR marking of 40 Exact Diagnostics infectious disease molecular quality controls. The controls are formulated with whole organisms in relevant matrices to simulate patient specimens. This design aims to ensure that the controls undergo the same workflow and process challenges as patient specimens during routine testing.

Revvity gets FDA approval for automated TB test

May 2025—Revvity announced that the FDA has approved the Auto-Pure 2400 liquid handling platform with the T-Spot.TB test, for in vitro diagnostic use. The Auto-Pure 2400 tests up to 24 samples per run and completes day-one T-Spot.TB workflows in less than three and a half hours.

Thermo Fisher launches IVDR-compliant capillary electrophoresis system

May 2025—Thermo Fisher Scientific has introduced the Applied Biosystems SeqStudio Flex Dx genetic analyzer, an IVDR-compliant capillary electrophoresis system for Sanger sequencing and fragment analysis in targeted genomic testing. The system includes three operating modes—in vitro diagnostic use, investigational use only, and research use only—and is available in eight- and 24-capillary configurations. It features four-plate capacity, continuous plate loading with auto-spectral calibration capabilities, and urgent sample reprioritization.

Verichem electrolyte testing reference materials

May 2025—Verichem Laboratories offers liquid stable, multianalyte kits of clinical reference materials intended for the calibration verification of electrolyte assays. The materials are designed to be treated as patient samples for use with systems using flame photometer, direct and indirect ion-selective electrode, or standard enzymatic/colorimetric testing methods. The electrolyte standard kit contains the analytes chloride, ionized calcium, lithium, potassium, and sodium and features a 21-month stability claim; the ISE standard kit contains chloride, lithium, potassium, and sodium and offers an 18-month stability claim. Carbon dioxide assays are covered by the CO2 standard kit and the standalone, ultrahigh CO2 standard level F, which have a 15-month stability claim.

Revolutionizing cancer diagnosis: the game-changing role of digital pathology and artificial intelligence

May 2025—The following is an extended release prepared by Agilent Technologies: Pathology plays a critical role in cancer care, encompassing the development of new treatments, diagnosis, staging, grading of disease, and clinical decision-making. While histopathological slides of tissue biopsies using hematoxylin and eosin staining and immunohistochemical staining remain central to this process, the rise of precision medicine testing is placing greater demands on pathology labs.

Diasorin C. auris assay launched in countries accepting the CE mark

April 2025—Diasorin announced the launch of its Simplexa C. auris Direct kit in all countries that accept the CE mark. The real-time polymerase chain reaction assay is used for the direct in vitro qualitative detection of C. auris DNA from a composite swab of the axilla and groin from patients suspected of C. auris colonization. The assay detects all six C. auris clades identified worldwide. Results are available in less than two hours on the Liaison MDX.

Advanced Instruments acquires Nova Biomedical

April 2025—Advanced Instruments, a subsidiary of Patricia Industries, announced the execution of a definitive agreement to acquire Nova Biomedical. Following the close of the transaction, Advanced Instruments and Nova Biomedical will merge and operate under the Nova Biomedical name. Byron Selman, president and CEO of Advanced Instruments, will lead the combined business, while Nova Biomedical founding shareholders Frank Manganaro, CEO, and Dr. Chung-Chang Young, EVP of R&D, will stay with the company in a consulting capacity.

Vitestro unveils Aletta robotic phlebotomy device

April 2025—Vitestro unveiled its CE-marked Aletta Autonomous Robotic Phlebotomy Device. Using AI-driven ultrasound guidance, robotic precision, and full automation, Aletta is designed to perform the entire blood draw process, from applying a tourniquet and preparing the skin to vein identification, venipuncture, automated tube handling, and bandage application. The device integrates advanced AI-driven Doppler ultrasound technology to optimize vein selection and needle placement.

ARUP expands AI-augmented screening tool

April 2025—ARUP Laboratories announced the expansion of its AI-augmented screening tool for the detection of human gastrointestinal parasites to include wet-mount slides. The tool uses scanned images to screen and eliminate negative specimens. It aims to reduce ergonomic stressors on laboratory staff, decrease turnaround time, and increase capacity.

MARKETPLACE

TRENDING